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Background
Patients with HIV/hepatitis C co-infection have glucose
and lipids metabolism alterations. Both HAART and HCV
contribute to lipids and glucose metabolic damage.
HAART-related insulin resistance contributes to the liver
steato/fibrosis evolution. Fewer data on metabolic and
hepatic tolerability are available in HIV/HCV co-infected
patients who switch from ZDV/LMV to TDF/FTC or ABC/
LMV.
Methods
A total of 150 HIV/HCV co-infected subjects with HIV-
RNA <50 copies/ml, on BID ZDV/LMV + atazanavir/riton-
avir (ATV/rtv) >6 months were randomized 1:1:1 to con-
tinue this regimen or to switch to QD TDF/FTC+ATV/rtv
or QD ABC/LMV +ATV/rtv. The primary end-point was
change in insulin resistance, calculated with HOMA score
(Homeostasis Model Assessment: fasting insulin UI/ml x
glucose mmol/l/22.5) at 48 weeks. Secondary end-points
included changes in absolute haemoglobin, AST, ALT,
fasting lipids, CD4, and viral load. Liver fibrosis assess-
ment by Fibroscan was planned at baseline and 96 weeks.
Two sample t-test for between group comparison was
used.
Summary of results
All 150 subjects were randomized: 49 to continue ZDV/
LMV; 50 to switch to TDF/FTC; and 51 to switch to ABC/
LMV. All patients were available for the 48-week analysis.
Subjects were well matched for baseline characteristics
and received a mean of 9 years prior ZDV/LMV. Median
stiffness score was 7.9. Cirrhosis was in 13.5%. At 48
weeks, all randomized subjects maintained the same
study therapy with VL <50 copies/ml. The change in
median HOMA score was 0.2, -0.4 and -0.1 in ZDV/LMV,
TDF/FTC and ABC/LMV, respectively (ZDV/LMV vs. TDF/
FTC: p < 0.001; ZDV/LMV vs. TDF/FTC: p > 0.001; TDF/
FTC vs. ABC/LMV: p = 0.06). Total cholesterol signifi-
cantly decreased in subjects who switched from ZDV/LMV
to TDF/FTC (-23 mg/dl; ZDV/LMV vs. TDF/FTC: p 0.005).
Change in median HDL-cholesterol was -2, +2.5, +4 mg/
dl in three arms, respectively (ZDV/LMV vs ABC/LMV: p >
0.001; ZDV/LMV vs. TDF/FTC: p > 0.001; TDf/FTC vs.
ABC/LMV: p 0.08). T CD4 cell count increased signifi-
cantly in subjects who switched from ZDV/LMV to TDF/
FTC (+23 cell/mm3: p 0.01) or ABC/LMV (+87 cell/mm3:
p = 0.001).
Conclusion
Switching from ZDV/LMV to TDF/FTC or ABC/LMV in
HIV/HCV persons treated with ATV/rtv provides a simpli-
fied QD regimen which maintains virological control and
improves both lipid and glucose parameters without
increase in hepatic toxicities.
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